July 22, 2014 3:31 AM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc., a biological therapeutics company, engages in the discovery, development, and commercialization of therapeutic treatments for gastrointestinal diseases and conditions. The company focuses on gastrointestinal physiology, metabolism, and gut adaptation associated with gastrointestinal diseases, including lactose intolerance, irritable bowel syndrome, crohn's disease, and ulcerative colitis. It develops RP-G28 for the treatment of lactose intolerance. The company was founded in 2004 and is based in Los Angeles, California.

1880 Century Park East

Suite 1100

Los Angeles, CA 90067

United States

Founded in 2004

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Head of Operations & Corporate Development
Age: 57
Head of Clinical Development
Age: 60
Chief of Clinical and Regulatory Development
Age: 59
Chief Business Officer
Age: 70
Compensation as of Fiscal Year 2014.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals, Inc. Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal

Ritter Pharmaceuticals, Inc. announced that Nutrition Journal has published the results of its phase 2 trial of RP-G28, a proprietary oligosaccharide under investigation as a potential treatment for lactose intolerance. The study manuscript entitled, 'Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial" is the first peer-reviewed presentation of the protocol, assessments and results which showed that RP-G28 dramatically reduced the pain and symptoms of lactose intolerant patients.

Ritter Pharmaceuticals, Inc. Appoints Larry Good as Chief Medical Officer; Expects to Design and Initiate its Next Phase 2 Clinical Studies of RP-G28 in Patients with Lactose Intolerance in Later 2013

Ritter Pharmaceuticals, Inc. announced the appointment of Larry I. Good, M.D., F.A.C.G. to the position of Chief Medical Officer. Dr. Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012. The company expects to design and initiate its next Phase 2 clinical studies of RP-G28 in patients with lactose intolerance later 2013.

Ritter Pharmaceuticals, Inc. Presents at 14th SoCalBio Investor Conference & Exhibition, Nov-07-2012 11:00 AM

Ritter Pharmaceuticals, Inc. Presents at 14th SoCalBio Investor Conference & Exhibition, Nov-07-2012 11:00 AM. Venue: Omni Hotel, 251 South Olive Street, Los Angeles, California, United States.

Similar Private Companies By Industry

Company Name Region
Sandoz Inc. United States
MyoKardia, Inc. United States
Asana BioSciences, LLC United States
Ember Therapeutics, Inc. United States
Tacere Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.